CBLL Ceribell Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: CBLL

Price (delayed)

$18.77

Market cap

$712.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.63

Enterprise value

$689.05M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 28

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography ...

Highlights
The gross profit has increased by 34% year-on-year and by 7% since the previous quarter
Ceribell's revenue has increased by 33% YoY and by 7% from the previous quarter
CBLL's quick ratio is down by 41% year-on-year but it is up by 7% since the previous quarter
The EPS has increased by 26% year-on-year but it has declined by 12% since the previous quarter
Ceribell's net income has decreased by 35% YoY and by 13% from the previous quarter
The equity has declined by 22% year-on-year and by 9% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Peers: MDT SYK BSX EW

Key stats

What are the main financial stats of CBLL

CBLL stock price

How has the Ceribell stock price performed over time
Intraday
9.25%
1 week
0.54%
1 month
-7.4%
1 year
9.51%
YTD
-14.41%
QTD
2.4%

Financial performance

How have Ceribell's revenue and profit performed over time
Revenue
$95.07M
Gross profit
$83.39M
Operating income
-$64.94M
Net income
-$60.37M
Gross margin
87.7%
Net margin
-63.5%
Ceribell's operating income has decreased by 43% YoY and by 11% QoQ
Ceribell's net income has decreased by 35% YoY and by 13% from the previous quarter
The gross profit has increased by 34% year-on-year and by 7% since the previous quarter
Ceribell's revenue has increased by 33% YoY and by 7% from the previous quarter

Price vs fundamentals

How does CBLL's price correlate with its fundamentals

Growth

What is Ceribell's growth rate over time

Valuation

What is Ceribell stock price valuation
P/E
N/A
P/B
5.02
P/S
7.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.25
The EPS has increased by 26% year-on-year but it has declined by 12% since the previous quarter
The equity has declined by 22% year-on-year and by 9% since the previous quarter
The P/B is 9% above the last 4 quarters average of 4.2
Ceribell's revenue has increased by 33% YoY and by 7% from the previous quarter
CBLL's price to sales (P/S) is 9% lower than its last 4 quarters average of 7.5

Efficiency

How efficient is Ceribell business performance
Ceribell's return on equity has surged by 77% YoY but it has decreased by 20% QoQ
CBLL's ROIC has soared by 60% YoY
The ROA has contracted by 18% from the previous quarter but it has grown by 7% YoY
The return on sales has declined by 7% since the previous quarter and by 3.2% year-on-year

Dividends

What is CBLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CBLL.

Financial health

How did Ceribell financials performed over time
CBLL's quick ratio is down by 41% year-on-year but it is up by 7% since the previous quarter
CBLL's current ratio is down by 40% year-on-year but it is up by 7% since the previous quarter
The debt is 84% smaller than the equity
The debt to equity rose by 33% year-on-year and by 14% since the previous quarter
The equity has declined by 22% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.